

Analyst / Media Teleconference 21 August 2009

Lonza

Non-binding proposal to acquire Patheon

Disclaimer

- Certain matters discussed in this presentation may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. The actual results may differ materially in the future from the forward-looking statements included in this presentation due to various factors. Furthermore, Lonza Group Ltd has no obligation to update the statements contained in this presentation.


Today's Announcement

- Proposal to acquire all of the outstanding restricted voting shares of Patheon Inc (TSX:PTI)
- Patheon's Special Committee of Independent Directors is supportive of Lonza's approach
- Indicated proposal price of USD 3.55 per share would value Patheon at USD ~460 million (market cap) and USD ~700 million (enterprise value)
- Patheon's Special Committee of Independent Directors has agreed to deal with Lonza on an exclusive basis during the due diligence period
- Completion of transaction dependent on satisfactory due diligence and contingent on acquiring more than 67% of Patheon

Background


- Lonza's stated strategy is to develop its offering across the full pharmaceutical research and manufacturing value chain
- Developing complementary activities of finished dosage development and manufacturing for both small molecule and biological active ingredients has been a corporate objective for several years
- By extending our offering, Lonza would be in a unique position to offer its customers manufacturing capability across the complete supply chain
- Patheon is one of a selected number of options that we have been evaluating over the past 12-24 months

Expanding our Life Science Value Chain




Patheon Overview

- Patheon is a world leader in finished dosage development and manufacturing for the global pharma industry
- Patheon sales are split approximately 80% commercial manufacturing (CMO) and 20% pharmaceutical development services (PDS)
- Patheon is in the top 3 of the global commercial manufacturing market and in the top 5 of the global PDS market
- Patheon manufactures more than 600 products in the full range of dosage forms (parenteral (sterile), solid, semi-solid and liquid)
- Patheon sales are split almost equally between NA and EU




Source: Company information



Source: Company information

Note: EBITDA excludes repositioning costs

Patheon Operations



- More than 4,000 employees worldwide, of which over 600 are development scientists
- Customer base comprises over 300 pharmaceutical companies in over 120 countries

Patheon – an attractive strategic opportunity

- Acquisition of Patheon would allow Lonza to provide customers with a unique full value offering of the pharmaceutical manufacturing value chain that runs from research to final manufacturing
- Patheon's diversified capabilities will allow Lonza to provide finished dosage development and manufacturing for small molecules and biologics – tablets through to sterile pre-filled syringes
- The ability to jointly develop biologics formulation capabilities and infrastructure will support both our current customer business as well as our pipeline customers
- Acquisition of Patheon would strengthen our product development offering and bring new additional pharmaceutical products to Lonza's manufacturing pipeline
- Potential acquisition earnings accretive in year 2 for EPS and EVA and will improve Lonza's return on assets

Next steps

- Need to complete satisfactory due diligence – expected to take approximately 6-8 weeks
- Proposed acquisition contingent on Lonza acquiring more than 67% of Patheon
- If formal offer is made, it is anticipated that the deal will complete in 2010
- Plan to finance the deal, if we move ahead, from existing cash resources and bond instruments

Analyst / Media Teleconference 21 August 2009

Lonza

Non-binding proposal to acquire Patheon